ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)

Inclusion Criteria: 1. Specimen collection screening * Karnofsky performance status (KPS) ≥ 60 at assessment prior to surgery * ≥ 18 and ≤ 70 years of age * Subject has been diagnosed with GBM and has undergone resection surgery followed by standard brain RT + concurrent temozolomide and adjuvant temozolomide, and progression occurred. The foregoing progression is defined as when patients with primary GBM experience an image or clinical deterioration after receiving standard of care. * Contrast-enhanced MRI suspects recurrent GBM * Supratentorial tumor * Must voluntarily sign and date informed consent form for specimen acquisition and future use, for study screening, approved by an Independent Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any study-specific procedures 2. Study screening * Karnofsky performance status (KPS) ≥ 60 at randomization * Submission of fresh tumor * Post-operation contrast-enhanced MRI scan must be done after surgical resection, with the intent for cyto-reduction ≥ 80% of the contrast-enhancing tumor mass * Histologically confirmed WHO grade IV glioma by pathology tissue screening * Subjects receiving bevacizumab as standard of care for given indication * Subject has adequate bone marrow, renal, and hepatic function prior to randomization as follow: 1. White blood cell (WBC) count ≥ 2,000/mm\^3; 2. Absolute neutrophil count (ANC) ≥ 1,000/mm\^3; 3. Platelets ≥ 100,000/mm\^3; 4. Hemoglobin (Hgb) ≥ 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable.); 5. Blood Urea Nitrogen (BUN) \< 30 mg/dL; 6. Creatinine \< 2 mg/dL; 7. Renal function: calculated creatinine clearance ≥ 30 mL/min; 8. Hepatic function: Total bilirubin ≤ 3 times upper limit of normal (ULN), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 times ULN; 9. Prothrombin Time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6 times ULN unless therapeutically warranted. * Subjects with recurrent GBM (Grade IV) are eligible for this protocol. An independent neuropathologist will review this diagnosis during the enrollment process * Must voluntarily sign and date informed consent form, for study participation, approved by an Independent Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any study-specific procedures Exclusion Criteria: 1. Specimen collection screening * Multifocal GBM * Prior invasive malignancy (except for non-melanomatous skin cancer; carcinoma in situ of breast, oral cavity or cervix) unless disease free for ≥ 2 years * Subject has used bevacizumab or immune checkpoint blockade to treat GBM * Lactating or pregnant female * Positive viral serology for HIV or syphilis at time of screening 2. Study screening * Subjects having a biopsy only at surgery or tumor cell insufficiency at preparation * Inability to undergo contrast-enhanced MRI scans * Subjects receiving investigational study drug for any indication or immunological-based treatment for any reason (Filgrastim may be used for prevention of severe neutropenia) * Inability to stop or decrease the use of corticosteroid doses to 4 mg/day prior to randomization * Tumor progression documented according to modified RANO criteria prior to randomization (approximately 5 weeks after surgery) * Severe, active comorbidity, defined as follow: 1. Subject with clinically defined Acquired Immune-Deficiency Syndrome (AIDS)-defining illness; 2. Subjects with acute hepatitis C or B infection; 3. Severe hepatic impairment (Child-Pugh category C or higher); 4. Electrocardiogram (ECG) with evidence of acute cardiac ischemia prior to randomization; 5. Transmural myocardial infarction or ischemia prior to enrollment; 6. Any other major medical illnesses or psychiatric impairments that in the Investigator's opinion will prevent administration or completion of protocol therapy * Subject used Gliadel wafer implant in surgery during screening process